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Abstract
Background: The WHO recently recommended the new Xpert MTB/RIF Ultra assay (Ultra) instead of the Xpert
MTB/RIF assay because Ultra has improved sensitivity. We report the diagnostic accuracy of Ultra for tuberculous
adenitis in a tuberculosis and HIV endemic setting.
Methods: We obtained fine-needle aspirates (FNA) and lymph node tissue by core-needle biopsy in adult patients
with peripheral lymphadenopathy of >20 mm. Ultra and mycobacterial culture were performed on FNA and tissue
specimens, with histological examination of tissue specimens. We assessed the diagnostic accuracy of Ultra against
a composite reference standard of ‘definite tuberculosis’ (microbiological criteria) or ‘probable tuberculosis’
(histological and clinical criteria).
Results: We prospectively evaluated 99 participants of whom 50 were HIV positive: 21 had ‘definite tuberculosis’, 15
‘probable tuberculosis’ and 63 did not have tuberculosis (of whom 38% had lymphoma and 19% disseminated
malignancy). Using the composite reference standard the Ultra sensitivity on FNA was 70% (95% CI 51–85; 21 of
30), and on tissue was 67% (45–84; 16/24) these were far superior to the detection of acid-fast bacilli on an FNA
(26%; 7/27); AFB on tissue (33%; 8/24); or tissue culture (39%; 9/23). The detection of granulomas on histology had
high senstivity (83%) but the lowest specficity. When compared with culture the Ultra on FNA had a sensitvity of
78% (40-97; 7/9) and tissue 90% (55-100; 9/10).
Conclusions: Ultra performed on FNA or tissue of a lymph node had good sensitivity and high specificity. Ultra
had a higher yield than culture and has the advantage of being a rapid test. Ultra on FNA would be an appropriate
initial investigation for lymphadenopathy in tuberculosis endemic areas followed by a core biopsy for
histopathology with a repeat Ultra on tissue if granulomas are present.
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Background
Lymph nodes and pleura are the most common sites of
involvement in extrapulmonary tuberculosis (EPTB),
which is more common in people living with HIV
(PLWH) [1]. EPTB is difficult to diagnose because it is
usually paucibacillary and conventional methods for
diagnosis, such as microscopy and culture, have low
yields, culture results may take several weeks and histo-
logical findings (e.g. granulomas) are not specific for tu-
berculosis. Following a systematic review, the WHO has
recommended that the rapid nucleic acid amplification
test Xpert MTB/RIF assay (Xpert) should be used in the
diagnosis of EPTB, including lymph node tissue [2]. In
this meta-analysis (13 studies, 955 samples), the pooled
sensitivity of Xpert on lymph node (tissue or fine needle
aspirate (FNA)) was 83.1% (95% CI 72–91), and pooled
specificity was 94% (95% CI 88–97%). Xpert has been re-
cently superseded by the Xpert MTB/RIF Ultra assay
(Ultra), which has greater sensitivity for the detection of
Mycobacterium tuberculosis complex in sputum speci-
mens but has lower specificity, especially in patients with
previous tuberculosis [3].
The Ultra differs from the earlier Xpert assay in a
number of ways: two different multicopy amplification
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targets (IS6110 and IS1081) have been added to improve
detection of M. tuberculosis and melting temperature-
based polymerase chain reaction (PCR) analysis (melting
curve analysis) is used to improve the detection of rifam-
picin resistance [4]. Because the limit of detection of
Ultra is lower (15.6 bacterial colony-forming units (CFU)
per ml compared with 114 CFU per ml with Xpert), the
greatest improvement in detection is likely to be in pau-
cibacillary samples. This has been demonstrated in cere-
brospinal fluid, where Ultra has much higher sensitivity
(95, 95% CI 77–99), versus Xpert at 45%,) with only a
marginally reduced specificity (95.6% vs 98.3%) which
was thought to be due to antecedent tuberculosis infec-
tion [5]. The performance on Ultra in lymph nodes has
only been tested in one small retrospective study on 10
frozen samples where it showed an improvement of 50%
compared with Xpert, (5/10 samples that were Xpert
negative and culture positive were positive on Ultra) [6].
In this study, we determined the diagnostic accuracy
of Ultra for the detection of M. tuberculosis in speci-
mens of lymph node obtained by FNA and core-needle
biopsy.
Methods
Study design and participants
We conducted a prospective diagnostic accuracy study of
Ultra on both FNA and lymph node core-needle biopsy tis-
sue in patients with suspected tuberculosis adenitis. The
study was performed at Groote Schuur Hospital, a tertiary
referral academic centre in Cape Town, South Africa. Eli-
gible study participants were adults (≥18 years), both in-
and outpatients, referred with enlarged lymph nodes of
>20mm in the widest diameter located in either the cer-
vical, axillary or inguinal region. Patients on tuberculosis
therapy were enrolled provided this had been given for <1
month (sub-analyses were done in patients on tuberculosis
therapy for <24 h). Patients with contraindications to core-
needle biopsy (low platelets, other coagulopathy and bleed-
ing risk, clinically unstable, site of biopsy unsafe) were
excluded. Written informed consent was obtained from all
participants. The Human Research Ethics Committee of
the Faculty of Health Sciences, University of Cape Town,
approved the study.
Patients came from within Groote Schuur and from
secondary level hospitals and day clinics in the referral
area. Results of prior tuberculosis investigations (sputum
Xpert or tuberculosis culture from any site within 3
months of referral, or urine lipoarabinomannan (LAM))
were recorded. Details of HIV status, tuberculosis treat-
ment and ART were obtained.
Data collection
Demographic information, symptoms, symptom duration,
HIV test result, and other TB investigations performed
were recorded at enrolment. Performance status was
graded according to the Eastern European Cooperative
Group (ECOG) [7]. The site of biopsy was recorded, along
with other sites of lymphadenopathy. The presence and
duration of constitutional symptoms (cough, loss of
weight night sweats) were specifically enquired about as
was the duration that the patient had noted the lymph-
adenopathy. Blood was taken for a full blood count with
differential, lactate dehydrogenase and HIV status and, if
positive, a CD4 count and a viral load for those on ART.
Study procedures and specimen collection
FNA was performed using a 22G needle and 5mL syringe;
further study procedures were determined by the volume
of the aspirate sample obtained as shown in Fig. 1. A core-
needle biopsy was only performed when < 0.5mL of case-
ous material was obtained by the aspirate, due to the risk
of causing a draining sinus. Initially, when both an FNA
and a biopsy were performed on a participant the Ultra
was performed only on the tissue, but there was a protocol
change after 25 patients and Ultra was performed on both
the FNA and tissue on the same patient. When a patient
had both an FNA and a core-needle biopsy the TB culture
was only performed on the tissue specimen. For the Ultra
on the FNA, the needle and syringe were flushed into a
sterile container containing 2mL of saline. An air-dried
Fig. 1 Study procedures
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smear for AFBs was made at the bedside from a second
FNA. For culture from the FNA, the aspirate was flushed
directed into mycobacterium culture medium (Middleb-
rook 7H9 broth medium). The core-needle biopsy was
performed by an automated biopsy gun (BARD Mag-
num™, CR Bard Inc., Covington, GA, USA) with a 14G
needle. If the lymph node was not obviously palpable the
biopsy was performed under ultrasound guidance. Two or
three cores were sent in formalin for histology (10–15mm
long), an additional core was cut in two with a sterile
blade and sent for culture and Ultra, both in 2ml of 0.9%
saline. If all of the tests performed were inconclusive, the
patient underwent a repeat core-needle biopsy or an exci-
sion biopsy at the discretion of the treating clinician.
Laboratory tests
FNA and tissue specimens were transported within 2 h
of collection to a centralized laboratory and processed
individually using standardised protocols by trained la-
boratory staff. The smear slide made at the bedside was
examined by Ziehl-Neelsen (ZN) for AFBs. The tissue
obtained by core-needle biopsy was crushed using pestle
and mortar. A small portion was smeared on a slide and
examined with a ZN stain for AFBs. Mycobacterial cul-
ture was performed using an automated liquid mycobac-
terial culture system (BACTEC™ MGIT™ 960; Becton,
Dickinson and Company, New Jersey, USA). Lymph
nodes are considered a sterile site and decontamination
was not performed prior to liquid biopsy. If the MGIT
flagged positive, one droplet was inoculated on 2% blood
agar and incubated for 24 h to check for bacterial
growth. If there was no bacterial growth, the MGIT was
reported as positive for mycobacterium, the specimen
was decontaminated with sodium hydroxide (1%) and
N-acety-L-cysteine and then repeat MGIT was per-
formed. Positive isolates from culture media were identi-
fied by acid-fast staining followed by MRTBDRplus
testing (Hain LifeScience, Hehren, Germany) to confirm
the presence of M. tuberculosis and rifampicin and iso-
niazid sensitivity.
For the Ultra, 1.4 mL of specimen reagent was added to
0.7 mL of aspirate or crushed tissue sample. Results were
reported as: invalid (no internal assay control detected);
not detected; or detected (with semi-quantitation: trace,
very low, low, medium, or high) and rifampicin resistance
(detected, not detected, or indeterminate). Staff perform-
ing Ultra were blinded to clinical and other microbio-
logical results.
Histological review was performed by a qualified
anatomical pathologist who was blinded to the results
of the ULTRA and did not have access to the culture,
but would have been able to see the results of AFBs
on microscopy. If granulomas were identified, a separ-
ate ZN stain was performed by the pathologist and a
Periodic acid–Schiff (PAS) stains were performed for
fungi.
Case definitions and statistical analysis
We assigned participants to one of three diagnostic
categories on the basis of clinical, histological and
microbiological investigations. Definite tuberculosis (cul-
ture-positive on FNA/ tissue for M. tuberculosis
OR AFBs identified on FNA/tissue) Probable tubercu-
losis (no other diagnosis that would account for lymph-
adenopathy with one or more of: macroscopic caseation
on FNA/tissue OR tuberculosis confirmed microbio-
logically [Ultra or culture] at a site other than the lymph
node (eg pulmonary) OR granulomas on FNA/tissue).
The third category was not tuberculosis (did not fulfil the
criteria for the other two categories). The Ultra diagnostic
accuracy was also reported separately using positive cul-
ture only as the reference standard.
Sample size estimation in diagnostic accuracy studies
depends on the prevalence of disease [8]. We were expect-
ing a high prevalence of tuberculosis based on a pilot
study we conducted of core-needle biopsy in HIV-positive
patients, 92% of whom had tuberculosis lymphadenitis [9],
but the proportion of patients with tuberculosis in our
study was lower than expected (40%) in a pilot phase of
our study. We estimated the sensitivity and specificity of
Ultra would both be around 90% based on the Cochrane
meta-analysis [9]. With a 40% prevalence of tuberculosis a
sample size of 87 is needed for 95% CI widths of 10% and
with sensitivity and specificity of 90% [8]. We inflated the
sample size to 100 because of uncertainties about the
diagnostic accuracy of Ultra.
We calculated sensitivity, specificity, negative predictive
value (NPV), positive predictive value (PPV) and likelihood
rations by defining true or false positives and true or false
negatives against the composite reference standard of prob-
able or definite tuberculosis for our primary analysis. As sec-
ondary analyses we also determined the accuracy of Ultra
using mycobacterial culture alone as the reference standard.
Data was entered into a REDCap® database and analysed
using the STATAv14 software package (StataCorp, College
Station, Texas, USA). Baseline clinical characteristics were
compared using the chi-squared or Fisher’s exact test for cat-
egorical variables and the Kruskal-Wallis test for continuous
variables. We counted invalid tests (i.e. Ultra-error) as nega-
tive results. This study is reported in accordance with the
Standards for Reporting of Diagnostic Accuracy Studies
Guidelines [10].
Role of the funding source
The funders had no role in study design, data collection,
data analysis, data interpretation, or writing of the re-
port. The corresponding author had full access to all the
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data in the study and had final responsibility for the de-
cision to submit for publication.
Results
Demographic and clinical characteristics
Between November 2017 and October 2018, 154 consecu-
tive patients were evaluated for suspected lymphadenop-
athy and we enrolled 99 participants for the study (Fig. 2).
Ultra of both FNA and core-needle biopsy were per-
formed in 56 participants, 25 participants had Ultra test-
ing of a core-needle biopsy only (prior to protocol
change), and 18 had Ultra testing of an FNA only. The
majority of participants (84%) were seen as outpatients. Of
the 51% (n = 50) participants who were HIV positive, 62%
(n = 31) were on ART and had a median CD4 count of
216 cells/mm3 (IQR 82–361) and in the participants on
ART, 42% (13/31) were virally suppressed with a viral load
lower than the detectable limit (<20 RNA copies/mL).
The final diagnosis was definite tuberculosis in 21 (21%),
probable tuberculosis in 15 (15%) and not tuberculosis in
63 (64%. Table 1 shows baseline characteristics of the par-
ticipants by diagnostic group.
The median age was significantly higher in the not tu-
berculosis group. The groups had similar HIV prevalence
and, in those who were HIV positive, similar median
CD4 counts. Previous tuberculosis, HIV prevalence and
CD4 count was similar in all diagnostic outcome groups.
Participants in all groups frequently reported cough,
night sweats and weight loss. There was also no signifi-
cant difference in the clinical examination findings of
the lymph node. Lymphocyte count, LDH and total
white cell count (WCC) were similar, however, anaemia
was more common in the participants with definite tu-
berculosis (present in 81%) compared with the other two
groups (p = 0.041).
A high proportion of participants had tuberculosis in-
vestigations prior to referral and the frequency of posi-
tive results were: sputum Xpert 3/22, urinary LAM 1/5,
and tuberculosis culture (5/15) (by site: urine 0/1, blood
1/2, sputum 4/12, lymph node 0/1 (tissue)). Chest x-ray
had been performed in 36% and reported as ‘suggestive
of tuberculosis’ by the referring clinician in 28% of these.
In the not tuberculosis group the final diagnosis was:
lymphoma in 24 (38%), other malignancy in 19 (30%),
reactive lymphadenopathy in 8 (13%), and miscellaneous
other causes (enlarged submandibular salivary gland
(n = 4), bacterial adenitis (n = 4), sarcoidosis (n = 2),
sinus histiocytosis (n = 1), branchial cleft cyst (n = 1)).
The diagnosis of ‘bacterial adenitis’ was based on > 0.5
mL caseous material with lymphadenopathy resolving
after drainage and antibiotics, and culture of the caseous
material not positive for tuberculosis. In the two cases of
sarcoidosis, granulomas were identified on histopath-
ology and chest computed tomography was compatible
with sarcoidosis, both participants went on to have a
lymph node excision biopsy which was negative on cul-
ture for tuberculosis.
Results of investigations and the performance of the Ultra
Participants underwent a number of different investiga-
tions for tuberculosis and histological examination on
the lymph node; Fig. 2 shows the participant test results
by diagnostic outcome groups. The diagnostic accuracy
of the reference tests (i.e. identification of AFBs, culture
Fig. 2 Trial profile. MTB =Mycobacterium tuberculosis. AFB = acid fast bacilli. FNA = fine-needle aspirate
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Table 1 Baseline characteristics by diagnostic group
Total (n = 99) Definite TB (n = 21) Probable TB (n = 15) Not TB (n = 63) P-value
Sex
Males 45 (45%) 9 (43%) 4 (27%) 32 (51%) 0.233
Females 54 (55%) 12 (57%) 11 (73%) 31 (49%)
Age (median [IQR]) 37 (30–49) 32 (28–35) 36 (31–41) 44 (32–57) 0.003
HIV status
Positive 50 (51%) 13 (62%) 8 (53%) 29 (46%) 0.442
Negative 49 (49%) 8 (38%) 7 (47%) 34 (54%)
On ARVS 31 (62%) 8 (62%) 7 (88%) 16 (55%) 0.263
CD4 count (cells/mm3, median [IQR]) 216 (82–361) 100 (55–254) 351 (88–497) 252 (92–361) 0.106
< 100 16 (32%) 6 (46%) 2 (25%) 8 (28%) 0.675
100–249 10 (20%) 3 (23%) 1 (13%) 6 (21%)
≥ 250 24 (48%) 4 (31%) 5 (63%) 15 (52%)
Performance Score
ECOG 0 49 (50%) 10 (48%) 9 (60%) 30 (48%) 0.979
ECOG 1 28 (28%) 6 (29%) 5 (33%) 17 (27%)
ECOG 2 4 (4%) 1 (5%) 0 3 (5%)
ECOG 3 16 (16%) 4 (19%) 1 (7%) 11 (17%)
ECOG 4 2 (2%) 0 0 2 (3%)
Patient Type
Inpatient 16 (16%) 4 (19%) 2 (13%) 10 (16%) 0.924
Outpatient 83 (84%) 17 (81%) 13 (87%) 53 (84%)
Previous tuberculosis 24 (24%) 6 (29%) 6 (40%) 12 (19%) 0.205
On tuberculosis treatment 21 (21%) 6 (29%) 6 (40%) 9 (15%) 0.059
Consistency of lymph node
Firm 81 (87%) 16 (80%) 12 (86%) 53 (90%) 0.491
Fluctuant 12 (13%) 4 (20%) 2 (14%) 6 (10%)
Symptoms
Cough 27 (27%) 6 (29%) 3 (20%) 18 (29%) 0.79
Weight loss 47 (47%) 13 (62%) 5 (33%) 29 (46%) 0.222
Night sweats 29 (29%) 8 (38%) 3 (20%) 18 (29%) 0.49
Location of lymph nodes
Unilateral 61 (62%) 13 (62%) 12 (80%) 36 (57%) 0.262
Bilateral 38 (38%) 8 (38%) 3 (20%) 27 (43%)
Lymph node FNA/biopsy site
Neck 85 (86%) 19 (90%) 14 (93%) 52 (83%) 0.881
Axilla 10 (10%) 2 (10%) 1 (7%) 7 (11%)
Inguinal 4 (4%) 0 0 4 (6%)
Blood results (median [IQR])
LDH (units/L) 267 (218–341) 292 (251–341) 218 (194–239) 273 (230–366) 0.006
Hb (g/dL) 12.1 (9.4–13.4) 10.5 (8.7–12.1) 11.8 (9.6–12.7) 12.4 (9.7–13.5) 0.041
WCC (cells × 10^9) 6.9 (4.9–9.1) 5.3 (4.0–8.0) 5.7 (4.8–7.3) 7.4 (5.2–9.9) 0.142
Lymphocytes (cells × 10^9) 1.7 (1.0–2.4) 1.2 (0.7–1.9) 1.7 (1.4–2.0) 1.7 (1.0–2.7) 0.197
P values <0.05 are shown in bold. Data are n/N; % (95% CI). ECOG Eastern Cooperative Oncology Group, LDH Lactate Dehydrogenase, Hb Haemoglobin, WCC
White Cell Count
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of lymph node tissue or aspirate) and against the com-
posite reference standard and against culture (of lymph
node tissue or FNA) are shown in Table 2. The diagnos-
tic accuracy of Ultra on both FNA and tissue is pre-
sented in Table 3 using the composite reference
standard, two sub-analyses are presented: the exclusion
of participants on tuberculosis therapy, and by using cul-
ture (tissue/FNA) alone as the reference test.
There were 55 participants who had an FNA and tissue
Ultra and histopathological examination of the lymph
node. The result concordance is shown in the Venn dia-
gram (Fig. 3). Of the 6 specimens that showed result dis-
cordance between FNA (negative) and tissue (positive), all
were ‘trace positive’ on the quantitative result and 2 of
these 6 were considered ‘false positives’. These two ‘false
positive’ results both had a histologically proven diagnosis
of cancer and one of the two had previous tuberculosis 12
years prior (neither were on tuberculosis treatment at the
time of biopsy). Although a dual diagnosis of tuberculosis
and cancer is possible, histological examination had no
features of tuberculosis in these two cases and was consid-
ered unlikely. Of the 5 with necrotising granulomas and
with a negative Ultra on both FNA and culture, 2 had def-
inite tuberculosis (1 culture positive, 1 AFB positive), 1
had probable tuberculosis and 2 had sarcoidosis.
There were 4 failed tests (invalid) in the tissue group,
and none in the FNA group. There were 12 ‘trace posi-
tive’ results, all in the tissue group and 2 of the 12 were
considered to be false positive as discussed under dis-
cordant results. Rifampicin resistance was identified in 2
of the 39 Ultra positive participants, which was con-
firmed on line-probe assay.
Discussion
Our prospective diagnostic accuracy study showed Ultra
sensitivity on FNA was 70% (95% CI 51–85; 21 of 30), and
on tissue 67% (45–84; 16/24); these were far superior to the
detection of acid-fast bacilli on an FNA (26% [11–46; 7/
27]), AFB on tissue (33% [16–55; 8/24], FNA culture [33%
(10–65; 4/12]) or tissue culture (39% [20–61; 9/23]). The
detection of granulomas on histology had high sensitivity
(83% [63–95; 20/24]) but had the lowest specificity of all
the tests (83% against culture). Our findings support the
use of Ultra on FNA as an initial test when tuberculosis ad-
enitis is suspected as Ultra has a high sensitivity, it is min-
imally invasive, requires no specialised equipment, and
gives a rapid result. Where the FNA does not yield a posi-
tive result, core-needle biopsy with histopathology and a
repeat Ultra on tissue if there are granulomas, would be
cost-effective and yield a high diagnostic rate both for tu-
berculosis and other conditions (notably malignancy).
We had high precision for Ultra specificity, which is a
key parameter given that specificity of Ultra was lower
than Xpert in sputum [3]. The sensitivity of Ultra on
FNA was 67% in our study, which is lower than the
87.6% reported in the Cochrane review [11], but they
found sensitivity was lower in adults and with lower
prevalence of tuberculosis.
The lower sensitivity of AFB detection and culture on
FNA and tissue was poor in our study and is consistent
with other studies [12–17]. From our data, the air-dried
smear for AFBs from the aspirate can be replaced by the
Ultra. Culture is limited both by low sensitivity on the
lymph node as well as a long turn-around-time, but it
still plays an important confirmatory role in diagnosis
particularly where drug resistance is suspected.
There is uncertainty surrounding the interpretation of
trace positivity of the Ultra from respiratory samples [3].
In our study, we only had ‘trace positive’ results on the
tissue (12) with none on the aspirate. Of the 6 discord-
ant FNA and tissue results, all were negative on aspirate
and trace positive on tissue and two of these 6 were false
positives. We suggest that trace positive Ultra results
from lymph node tissue or FNA be regarded as positive,
but that this result is interpreted together with clinical
and histopathological findings. Where the histopatho-
logical findings do not show necrotizing granulomas; an
excision biopsy would be preferred as this scenario is
most likely to represent a false positive result.
Our study has several limitations. First, without a perfect
reference standard we needed to define a reference standard;
we tried to address this by clearly defining ‘definite’ and
‘probable’ tuberculosis. The most stringent definition for a
true positive would be culture positivity. We felt it was
Table 2 Sensitivity and specificity of each diagnostic test using the composite reference standard and culture of either lymph node
tissue or FNA








AFBs on FNA (n = 61) 7/27; 26% (11–46) 34/34; 100% (90–100) 3/8; 38% (9–76) 49/53; 92% (82–98)
FNA culture (n = 17) 4/12; 33% (10–65) 5/5; 100% (48–100) 4/4; 100% (40–100) 13/13; 100% (75–100)
AFBs on tissue (n = 81) 8/24; 33% (16–55) 57/57; 100% (94–100) 4/10; 40% (12–74) 67/71; 94% (86–98)
Tissue culture (n = 75) 9/23; 39% (20–61) 52/52; 100% (93–100) 9/10; 90% (55–100) 65/65; 100% (94–100)
Necrotising granulomas on histology
(n = 81)
20/24; 83% (63–95) 55/57; 96% (88–100) 10/10; 100% (69–
100)
59/71; 83% (72–91)
Data are n/N; % (95% CI). FNA Fine-needle aspirate, AFBs Acid fast bacilli, PPV Positive predictive value, NPV Negative predictive value
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justifiable to include detection of AFB in the case definition
for definite tuberculosis because adenitis caused by nontu-
berculous mycobacteria is rare (typically only seen in non-
BCG immunized children [17]) and we know that culture
has relatively low sensitivity on lymph nodes, in particular
on FNA [18, 19]. Futhermore, in our cohort the culture
positive cases were all of m. tuberculosis with no other types
of tuberculosis cultured. The problems defining case positiv-
ity especially in extra-pulmonary tuberculosis is a familiar
challenge, in the Cochrane systematic review of Xpert for
extra-pulmonary tuberculosis the specificity of Xpert on
FNA was 86% when culture was the reference standard, but
in the latent class meta-analysis model with a less stringent
reference standard improved to 99%, which is likely to be a
much more accurate reflection of specificity [11]. Further
impacting culture detection rates in our study is that we in-
cluded participants on tuberculosis therapy; a sub-analysis
was performed excluding these participants (Table 3) where
it did not appear to affect the results. Given the low yield for
culture, our detection rates might have been higher if we
sent both the aspirate and tissue for tuberculosis culture but
due to financial constraints, we only sent one specimen for
culture (either the aspirate or the tissue).
A major strength of our study is that is a pro-
spective cohort study that tests the use of the Ultra
in a ‘real-world’ clinic setting and can therefore ad-
dress both diagnostic accuracy as well as clinical
utility. We included participants in whom the final
diagnosis of cervical swelling was not lymphadenop-
athy; this could be seen a limitation in that in these
few situations the material tested was not lymph
node tissue (e.g submandibular gland tissue) but
there were no false positives in these patients and
this answers an important clinical question about the
risk of false positive results if tissue other than
lymph node is biopsied. Other study strengths in-
clude the use of a standard protocol, and a single
operator performing the FNA and core-needle
biopsy.
Conclusion
The Ultra on FNA and on tissue had good sensitiv-
ity, and high specificity in our primary analysis.
Ultra on FNA is a cheap and simple bedside pro-
cedure with a fast turnover time and is the most
appropriate the initial diagnostic test where tubercu-
losis adenitis is suspected. AFBs on air-dried smear
on FNA has low sensitivity and should be replaced
by the Ultra. Core-needle biopsy with a repeat Ultra
when granulomas are identified is an appropriate
second investigation as it may confirm tuberculosis
infection and importantly allows for histological
examination and early diagnosis of lymphoma or
other malignancies without the need for excision
biopsy.
Table 3 Diagnostic accuracy of Ultra on FNA and tissue measured against the composite reference standard and culture
Sensitivity Specificity PPV NPV LR+ LR-
Composite reference standard
Ultra on FNA (n = 73 participants) 21/30; 70% (51–85) 43/43; 100% (92–100) 100% 83% inv 0.3
Ultra on tissue (n = 81 participants) 16/24; 67% (45–84) 55/57; 96% (88–99) 89% 87% 16.8 0.3
Excluding the 21 participants on tuberculosis therapy>24 h
Ultra on FNA (n = 57 participants) 12/20; 60% (36–81) 37/37; 100% (91–100) 100% 82% inv 0.4
Ultra on tissue (n = 66 participants) 10/18; 56% (31–78) 46/48; 96% (86–99) 83% 85% 14 0.5
Culture as the reference standard (n = 99 participants)
Ultra on FNA (n = 73 participants) 7/9; 78% (40–97) 50/64; 78% (66–87) 33% 96% 3.5 0.3
Ultra on tissue (n = 81 participants) 9/10; 90% (55–100) 62/71; 87% (77–94) 50% 98% 6.9 0.1
Data are n/N; % (95% CI). FNA Fine-needle aspirate, AFBs Acid fast bacilli, PPV Positive predictive value, NPV Negative predictive value, LR likelihood ratio
Fig. 3 Venn diagram to show the overlap in yield in the tests with
the highest yeild for tuberculous adenitis. TB = tuberculosis;
FNA = fine-needle aspirate
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